Review ArticlesTargeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin LymphomaAlperovich, Anna MD; Younes, Anas MDAuthor Information From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Anas Younes, MD, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065. E-mail: email@example.com. The Cancer Journal: January/February 2016 - Volume 22 - Issue 1 - p 23-26 doi: 10.1097/PPO.0000000000000168 Buy Metrics Abstract The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.